Pharma BD Deal Intelligence

Bristol-Myers Squibb Company / IFM Therapeutics, LLC

2017 · Acquisition/Merger · $2.3B · Complete

Announcement Sentiment

Positive

BMS agreed to acquire IFM Therapeutics for $300M upfront plus up to $2.02B in contingent payments tied to first products from the two innate immunity programs (~$2.32B aggregate). The deal gave BMS full rights to IFM's preclinical STING and NLRP3 agonist programs targeting innate immunity in oncology. Awarded Clarivate's 2017 Deal of the Year. Closed September 7, 2017.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Stalled

Assessment window: 5yr post-close.

Key facts

Announced Aug 30, 2017
Closed Sep 07, 2017
Deal value $2.3B
Deal type Acquisition/Merger
Therapeutic area Oncology (innate immunity-based immuno-oncology)
Indications Oncology (innate immunity-based immuno-oncology)
Key assets Preclinical STING and NLRP3 agonist programs
Mechanism STING (Stimulator of Interferon Genes) agonist; NLRP3 inflammasome agonist

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals